Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
By:
References
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net.
Blood 2010;115 : 454-74. - Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al.
ITS Classification of tumours of haematopoietic and lymphoid tissues . Lyon: IARC Press; 2008. - Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome.
N Engl J Med 2009;361 : 1058-66. - Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated
IDH1 andIDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2-hydrozyglutarate.Cancer Cell 2010;17 : 225-34. - Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding
IDH1 andIDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.Blood 2010;116 : 2122-6. - Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, et al.
IDH1 andIDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia withNPM1 mutation withoutFLT3 internal tandem duplication.J Clin Oncol 2010;28 : 3636-43. - Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
J Clin Oncol 2010;28 : 3717-23. - Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, et al.
IDH1 andIDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.J Clin Oncol 2010;28 : 2348-55. - Zhou KG, Jiang LJ, Shang Z, Wang J, Huang L, Zhou JF, et al. Potential application of
IDH1 andIDH2 mutations as prognostic indicators in nonpromyelocytic acute myeloid leukemia: a meta-analysis.Leuk Lymphoma 2012;53 : 2423-29. - Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, et al.
DNMT3A andIDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.Leukemia 2014;28 : 1774-83. - Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, et al.
IDH1 andIDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking theNPM1 mutation.Eur J Haematol 2014;92 : 471-7. - Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU. Molecular alterations of isocitrate dehydrogenase 1 and 2 (
IDH1 andIDH2 ) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.J Hematol Oncol 2012;5 : 5. - Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, et al. Prognostic impact of
IDH2 mutations in cytogenetically normal acute myeloid leukemia.Blood 2010;116 : 614-6. - Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, et al. Impact of
IDH1 R132 mutations and anIDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.J Clin Oncol 2010;28 : 2356-64. - Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
Blood 2010;115 : 2749-54. - Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T.
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutatedNPM1 status.Blood 2010;116 : 5486-96. - Nomdedéu J, Hoyos M, Carricondo M, Esteve J, Bussaglia E, Estivill C, et al. Adverse impact of
IDH1 andIDH2 mutations in primary AML: experience of the Spanish CETLAM group.Leuk Res 2012;36 : 990-7. - Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N Engl J Med 2012;366 : 1079-89. - Patel JP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, et al. Acute myeloid leukemia with
IDH1 orIDH2 mutation: frequency and clinicpatho-logic features.Am J Clin Pathol 2011;135 : 35-45. - Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, et al. Prognostic significance of alterations in
IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.Cancer 2012;118 : 2665-73. - Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
Leukemia 2011;25 : 246-53. - Chou WC, Peng KY, Lei WC, Ko BS, Tsay W, Kuo CH, et al. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.
Leukemia 2012;26 : 527-9. - Jeziskova I, Razga F, Bajerova M, Racil Z, Mayer J, Dvorakova D.
IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status.Leuk Lymphoma 2010;51 : 2285-7. - Kuzmanovic M, Tosic N, Colovic N, Karan-Djurasevic T, Spasovski V, Radmilovic M, et al. Prognostic impact of
NPM1 mutations in Serbian adult patients with acute myeloid leukemia.Acta Haematol 2012;128 : 203-12. - Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.
Ann Intern Med 1985;103 : 620-5. - Shaffer LG, Slovak ML, Campbell LJ.
An international system for human cytogenetic nomenclature . Basel: Karger; 2009. - Sorror ML, Marris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoetic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogenic HCT.
Blood 2005;106 : 2912-9. - Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
Am J Clin Oncol 1982;5 : 649-55. - Cheson BD, Bennet JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcome, and reporting standards for therapeutic trials in acute myeloid leukemia.
J Clin Oncol 2003;21 : 4642-9. - Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al. Internal tandem duplication of
FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).Leukemia 1997;11 : 1447-52. - Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of
FLT3 in human hematologic malignancies.Blood 2001;97 : 2434-9. - Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. GIMEMA Acute Leukemia Working Party: cytolasmatic nucleophosmin in acute myelogenous leukemia with normal karyotype.
N Engl J Med 2005;352 : 254-66. - Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic
IDH1 andIDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.Cancer Cell 2010;18 : 553-67. - Kelly LM, Gilliland DG. Genetics of myeloid leukemias.
Annu Rev Genomics Hum Genet 2002;3 : 179-98. - Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications.
J Clin Oncol 2005;23 : 6285-95. - Green A, Beer P. Somatic mutations of
IDH1 andIDH2 in the leukemic transformation of myeloproliferative neoplasms.N Engl J Med 2010;362 : 369-70. - Chotirat S, Thongnoppakhun W, Wanachiwanawin W, Auewarakul CU. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (
IDH1 andIDH2 ) in preleukemic disorders.Blood Cells Mol Dis 2015;54 : 286-91. - Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Cancer Res 2010;70 : 447-52. - Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, et al.
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration withJAK2 V617F.Leukemia 2012;26 : 475-80. - Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
J Exp Med 2010;207 : 339-44.
Language: English
Page range: 385 - 393
Submitted on: Mar 28, 2016
Accepted on: Jun 18, 2016
Published on: Sep 8, 2016
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2016 Marijana Virijevic, Teodora Karan-Djurasevic, Irena Marjanovic, Natasa Tosic, Mirjana Mitrovic, Irena Djunic, Natasa Colovic, Ana Vidovic, Nada Suvajdzic-Vukovic, Dragica Tomin, Sonja Pavlovic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.